The Effect of Pemetrexed Mediated ENT-1 Modulation of [18F]FLT on Non-Small Cell Lung Cancer Tissue Pharmacokinetics.
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2016
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 May 2016 Status changed from recruiting to completed.
- 08 Jul 2015 Accrual to date is 91% according to United Kingdom Clinical Research Network record.
- 04 Jul 2015 Planned End Date changed from 29 Mar 2015 to 31 Mar 2015 as reported by UKCRN.